Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Toda la web
Inicio Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) Diagnostic yield of baseline and follow-up PET/CT studies in ablative therapy fo...
Journal Information
Vol. 31. Issue 6.
Pages 301-307 (November - December 2012)
Share
Share
Download PDF
More article options
Visits
1133
Vol. 31. Issue 6.
Pages 301-307 (November - December 2012)
Original article
Diagnostic yield of baseline and follow-up PET/CT studies in ablative therapy for non-small cell lung cancer
Rentabilidad diagnóstica de los estudios PET/TC basal y de seguimiento en la terapia ablativa del cáncer de pulmón de células no pequeñas
Visits
1133
J.L. Pou Uchaa,
Corresponding author
Javier.Lucas.Pou.Ucha@gmail.com

Corresponding author.
, J.M. Nogueiras Alonsob, A.M. Alvarez Paeza, B.A. Suarez Arfenonic, A. Serena Puiga, A.M. Lopez Lopezb, J. Barandela Salgadoa, L.M. Campos Villarinoa, M. Casal Rivasd, R. Guitian Iglesiasb
a Unidad de Medicina Nuclear, Complejo Hospitalario Universitario de Vigo, Vigo, Spain
b Unidad de Medicina Nuclear, Galaria, Vigo, Spain
c Unidad de Radiodiagnóstico, Complejo Hospitalario Universitario de Vigo, Vigo, Spain
d Unidad de Radiología Intervencionista, Complejo Hospitalario Universitario de Vigo, Vigo, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Tables (4)
Table 1. Inclusion and exclusion criteria for the selection of the patients in the study.
Table 2. Statistical results of the times (in months) between the PET/CT and ablation (left columns) and the metabolic activities observed in the baseline and follow up PET/CT.
Table 3. Results of ablation, response to treatment, new posterior therapeutic strategies, current clinical status of the patient.
Table 4. Morphological and functional studies at baseline and prior to and after the ablation intervention.
Show moreShow less
Abstract

Although they have proven effectiveness, radiofrequency and microwave ablation techniques have a high rate of partial responses. Diagnostic studies that anticipate the changes in morphology are essential for earlier detection of residual viable tumor tissue or local recurrences to identify patients who will benefit from a new treatment. Our study has determined the diagnostic yield of PET/CT studies at baseline and follow-up and adequate time between them and the ablation intervention. Seven patients with single tumor lesion with a total of 8 ablations were included. CT and PET/CT studies were performed at baseline and follow-up after ablation. Average times between PET studies at baseline and follow-up and the ablative therapy were 1.8 and 3.4 months, respectively. Mean scores in metabolic activities of the PET at baseline and follow-up were 7.6 and 4.3g/ml of SUVmax, respectively. The Dual Time Point technique helped to identify viable tissue after ablation in 3 cases. Follow-up PET/CT studies have conditioned the various treatment strategies adopted by clinical oncologists. The high yield of the PET/CT study including the Dual Time Point technique may be considered as a study replacement of initial and follow-up contrast-enhanced CT before and after treatment with RFA and AMO, this achieving considerable reduction in the exposure to high radiation levels. We propose conducting the first PET/CT follow-up study at 3 months of the RFA and AMO.

Keywords:
Positron emission tomography
18FFluorodeoxyglucose
Radiofrequency ablation
Treatment response
Non-small cell lung cancer
Resumen

Aunque con efectividad probada, las técnicas de ablación por radiofrecuencia y microondas presentan un elevado índice de respuestas parciales. Es imprescindible contar con estudios diagnósticos que se anticipen a los cambios morfológicos para una detección más temprana del tejido tumoral residual viable o de recurrencias locales para determinar los pacientes que serán beneficiados de un nuevo tratamiento. Determinamos mediante nuestro estudio la rentabilidad diagnóstica de los estudios de PET/TC basal y de seguimiento y el tiempo adecuado entre estos y la intervención por ablación. Incluimos 7 pacientes con lesión tumoral única con un total de 8 ablaciones. Hemos realizado estudios CT y PET/TC basales y de seguimiento tras ablación. Los tiempos medios entre estudios PET basales y de seguimiento y la terapia ablativa fueron 1,8 y 3,4 meses respectivamente. Las cuentas medias en actividades metabólicas de los PET basales y de seguimiento han sido de 7,6 y 4,3g/ml de SUVmax respectivamente. La técnica de Dual Time Point ayudó en 3 casos a identificar tejido viable tras ablación. Los estudios de seguimiento PET/TC han condicionado las diversas estrategias terapéuticas adoptadas por los oncólogos clínicos. El alto rendimiento del estudio PET/TC incluyendo la técnica de Dual Time Point puede plantearse como estudio de sustitución de los CT con CIV basales y de seguimiento previo y posterior al tratamiento con ARF o AMO logrando reducir de manera considerable la exposición a altas cifras de radiación. Proponemos realizar el primer estudio PET/TC de seguimiento a los 3 meses de realizada la ARF o AMO.

Palabras clave:
Tomografía por emisión de positrones
F18-Fluorodeoxiglucosa
Ablación por radiofrecuencia
Respuesta terapéutica
Cáncer de pulmón de células no pequeñas

Article

These are the options to access the full texts of the publication Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos